IPO registrations (S-1, F-1) · Registrants
FF EAI Robotics Ecosystem Inc.
- SEC CIK
- 1460702 · filings on EDGAR ↗
- Name on the registration
- AIxCrypto Holdings, Inc.
- Former names
- AIxCrypto Holdings, Inc. (2025–2026); Qualigen Therapeutics, Inc. (2020–2025); RITTER PHARMACEUTICALS INC (2009–2020)
- Registration
- Form S-1, first filed 2015-03-23, last 2026-09-09; 11 initial registrations, 21 amendments
- Outcome
- Final prospectus filed 2015-06-26; declared effective 2015-06-24; withdrawal requested 2025-09-24
- Industry (SIC)
- Finance Services 6199
- Incorporated in
- DE
- Business address
- 1990 E. GRAND AVENUE, El Segundo, CA 90245
- EIN
- 26-3474527
- Ticker
- FFR (Nasdaq)
- EDGAR entity type
- operating
- Insiders and CEO pay
- FF EAI Robotics Ecosystem Inc. on the corporate pages
Offering terms
- Final price
- $5.00 per share (424B4 filed 2015-06-26, an initial public offering)
- Shares sold
- 4,000,000
- Gross proceeds
- $20,000,000 before underwriting discounts and any over-allotment option
- Listing
- Nasdaq under the symbol RTTR
- Lead underwriters
- Aegis Capital
- Syndicate
- Chardan
Read from the cover pages of the filings listed under “Prospectus pages read” below; check the document for anything that matters.
On this site
- Form 5500 plan sponsor: QUALIGEN THERAPEUTICS, INC EXACT (EIN (EXACT))
- Form D issuer: Qualigen Therapeutics, Inc. EXACT (CIK (EXACT))
- SEC filer: AIxCrypto Holdings, Inc. EXACT (CIK (EXACT))
- Person page: Andrew J Ritter Fuzzy (officer, director or 10% owner on the company's Forms 3, 4 and 5 (Director,Officer))
- Person page: Michael D Step Fuzzy (officer, director or 10% owner on the company's Forms 3, 4 and 5 (Director,Officer))
Filings 57
| Filed | Form | What it is | Name as filed | EDGAR |
|---|---|---|---|---|
| 2015-03-23 | S-1 | S-1 (registration) | RITTER PHARMACEUTICALS INC | 0001571049-15-002195 ↗ |
| 2015-04-24 | S-1/A | S-1/A (amendment) | RITTER PHARMACEUTICALS INC | 0001571049-15-003129 ↗ |
| 2015-05-08 | S-1/A | S-1/A (amendment) | RITTER PHARMACEUTICALS INC | 0001571049-15-003855 ↗ |
| 2015-05-22 | S-1/A | S-1/A (amendment) | RITTER PHARMACEUTICALS INC | 0001571049-15-004555 ↗ |
| 2015-06-08 | S-1/A | S-1/A (amendment) | RITTER PHARMACEUTICALS INC | 0001571049-15-004929 ↗ |
| 2015-06-19 | S-1/A | S-1/A (amendment) | RITTER PHARMACEUTICALS INC | 0001571049-15-005174 ↗ |
| 2015-06-24 | EFFECT | EFFECT (declared effective) | RITTER PHARMACEUTICALS INC | 9999999995-15-001718 ↗ |
| 2015-06-26 | 424B4 | 424B4 (final prospectus) | RITTER PHARMACEUTICALS INC | 0001571049-15-005347 ↗ |
| 2015-12-31 | S-1 | S-1 (registration) | RITTER PHARMACEUTICALS INC | 0001493152-15-006507 ↗ |
| 2016-01-19 | S-1/A | S-1/A (amendment) | RITTER PHARMACEUTICALS INC | 0001493152-16-006847 ↗ |
| 2016-02-11 | EFFECT | EFFECT (declared effective) | RITTER PHARMACEUTICALS INC | 9999999995-16-003737 ↗ |
| 2016-06-07 | EFFECT | EFFECT (declared effective) | RITTER PHARMACEUTICALS INC | 9999999995-16-004845 ↗ |
| 2016-08-23 | EFFECT | EFFECT (declared effective) | RITTER PHARMACEUTICALS INC | 9999999995-16-005492 ↗ |
| 2016-12-16 | S-1 | S-1 (registration) | RITTER PHARMACEUTICALS INC | 0001493152-16-015971 ↗ |
| 2017-02-09 | S-1/A | S-1/A (amendment) | RITTER PHARMACEUTICALS INC | 0001493152-17-001273 ↗ |
| 2017-02-13 | EFFECT | EFFECT (declared effective) | RITTER PHARMACEUTICALS INC | 9999999995-17-000367 ↗ |
| 2017-07-03 | S-1 | S-1 (registration) | RITTER PHARMACEUTICALS INC | 0001493152-17-007461 ↗ |
| 2017-07-18 | S-1/A | S-1/A (amendment) | RITTER PHARMACEUTICALS INC | 0001493152-17-007882 ↗ |
| 2017-07-19 | S-1/A | S-1/A (amendment) | RITTER PHARMACEUTICALS INC | 0001493152-17-007981 ↗ |
| 2017-09-07 | S-1/A | S-1/A (amendment) | RITTER PHARMACEUTICALS INC | 0001493152-17-010318 ↗ |
| 2017-09-18 | S-1/A | S-1/A (amendment) | RITTER PHARMACEUTICALS INC | 0001493152-17-010706 ↗ |
| 2017-09-28 | S-1/A | S-1/A (amendment) | RITTER PHARMACEUTICALS INC | 0001493152-17-010992 ↗ |
| 2017-09-28 | S-1/A | S-1/A (amendment) | RITTER PHARMACEUTICALS INC | 0001493152-17-011016 ↗ |
| 2017-09-28 | EFFECT | EFFECT (declared effective) | RITTER PHARMACEUTICALS INC | 9999999995-17-002493 ↗ |
| 2017-09-29 | S-1MEF | S-1MEF (added securities) | RITTER PHARMACEUTICALS INC | 0001493152-17-011060 ↗ |
| 2017-10-02 | 424B4 | 424B4 (final prospectus) | RITTER PHARMACEUTICALS INC | 0001493152-17-011152 ↗ |
| 2018-11-30 | EFFECT | EFFECT (declared effective) | RITTER PHARMACEUTICALS INC | 9999999995-18-003017 ↗ |
| 2019-07-24 | S-1 | S-1 (registration) | RITTER PHARMACEUTICALS INC | 0001493152-19-011038 ↗ |
| 2019-08-01 | EFFECT | EFFECT (declared effective) | RITTER PHARMACEUTICALS INC | 9999999995-19-001791 ↗ |
| 2019-08-01 | EFFECT | EFFECT (declared effective) | RITTER PHARMACEUTICALS INC | 9999999995-19-001792 ↗ |
| 2020-04-09 | EFFECT | EFFECT (declared effective) | RITTER PHARMACEUTICALS INC | 9999999995-20-000719 ↗ |
| 2022-06-29 | EFFECT | EFFECT (declared effective) | Qualigen Therapeutics, Inc. | 9999999995-22-001926 ↗ |
| 2022-08-05 | EFFECT | EFFECT (declared effective) | Qualigen Therapeutics, Inc. | 9999999995-22-002281 ↗ |
| 2023-01-05 | EFFECT | EFFECT (declared effective) | Qualigen Therapeutics, Inc. | 9999999995-23-000047 ↗ |
| 2023-06-13 | S-1 | S-1 (registration) | Qualigen Therapeutics, Inc. | 0001493152-23-021102 ↗ |
| 2023-09-07 | EFFECT | EFFECT (declared effective) | Qualigen Therapeutics, Inc. | 9999999995-23-002594 ↗ |
| 2023-10-03 | S-1/A | S-1/A (amendment) | Qualigen Therapeutics, Inc. | 0001493152-23-035096 ↗ |
| 2024-05-02 | EFFECT | EFFECT (declared effective) | Qualigen Therapeutics, Inc. | 9999999995-24-001339 ↗ |
| 2024-05-06 | S-1/A | S-1/A (amendment) | Qualigen Therapeutics, Inc. | 0001493152-24-017806 ↗ |
| 2024-08-07 | S-1/A | S-1/A (amendment) | Qualigen Therapeutics, Inc. | 0001493152-24-030612 ↗ |
| 2024-08-09 | S-1/A | S-1/A (amendment) | Qualigen Therapeutics, Inc. | 0001493152-24-030954 ↗ |
| 2024-08-22 | S-1/A | S-1/A (amendment) | Qualigen Therapeutics, Inc. | 0001493152-24-033560 ↗ |
| 2024-09-04 | EFFECT | EFFECT (declared effective) | Qualigen Therapeutics, Inc. | 9999999995-24-002713 ↗ |
| 2024-09-06 | 424B4 | 424B4 (final prospectus) | Qualigen Therapeutics, Inc. | 0001493152-24-035279 ↗ |
| 2024-10-24 | S-1 | S-1 (registration) | Qualigen Therapeutics, Inc. | 0001493152-24-042395 ↗ |
| 2024-12-09 | S-1 | S-1 (registration) | Qualigen Therapeutics, Inc. | 0001493152-24-049319 ↗ |
| 2024-12-19 | EFFECT | EFFECT (declared effective) | Qualigen Therapeutics, Inc. | 9999999995-24-003842 ↗ |
| 2025-09-16 | S-1 | S-1 (registration) | Qualigen Therapeutics, Inc. | 0001493152-25-013721 ↗ |
| 2025-09-24 | RW | RW (withdrawal request) | Qualigen Therapeutics, Inc. | 0001493152-25-014805 ↗ |
| 2025-09-26 | EFFECT | EFFECT (declared effective) | Qualigen Therapeutics, Inc. | 9999999995-25-003121 ↗ |
| 2025-12-04 | S-1 | S-1 (registration) | AIxCrypto Holdings, Inc. | 0001493152-25-026046 ↗ |
| 2025-12-11 | EFFECT | EFFECT (declared effective) | AIxCrypto Holdings, Inc. | 9999999995-25-003684 ↗ |
| 2026-07-27 | S-1 | S-1 (registration) | AIxCrypto Holdings, Inc. | 0001493152-26-034816 ↗ |
| 2026-08-18 | S-1/A | S-1/A (amendment) | AIxCrypto Holdings, Inc. | 0001493152-26-039049 ↗ |
| 2026-09-04 | S-1/A | S-1/A (amendment) | AIxCrypto Holdings, Inc. | 0001493152-26-041428 ↗ |
| 2026-09-09 | S-1/A | S-1/A (amendment) | AIxCrypto Holdings, Inc. | 0001493152-26-041886 ↗ |
| 2026-09-14 | EFFECT | EFFECT (declared effective) | AIxCrypto Holdings, Inc. | 9999999995-26-002961 ↗ |
Prospectus pages read 2
| Filed | Form | Read as | Range | Price | Shares | Proceeds | Listing | Underwriters | What was found | Document |
|---|---|---|---|---|---|---|---|---|---|---|
| 2015-06-19 | S-1/A | registration statement | $5.00 | 4,000,000 | $20,000,000 | Nasdaq RTTR | 3 | primary document; price sentence, shares headline, proceeds computed, cover names 3 | document ↗ | |
| 2015-06-26 | 424B4 | final prospectus | $5.00 | 4,000,000 | $20,000,000 | Nasdaq RTTR | 2 | primary document; price sentence, shares headline, proceeds table, cover names 2 | document ↗ |
Officers, directors and large holders Forms 3, 4 and 5
| Insider | Role | Title | Filings | Years | On this site |
|---|---|---|---|---|---|
| Doyle Noah | Director; Director,TenPercentOwner | 10 | 2015–2020 | ||
| FOEHR MATTHEW W | Director | 13 | 2015–2020 | ||
| Javelin Venture Partners I SPV I, LLC | TenPercentOwner | 2 | 2015 | ||
| Javelin Venture Partners, L.P. | TenPercentOwner | 4 | 2015–2017 | ||
| Lynn Samuel O | Officer | CFO | 1 | 2015 | |
| MAIER PAUL V | Director | 6 | 2015–2020 | ||
| PROEHL GERALD T | Director | 5 | 2015–2018 | ||
| Ritter Andrew J | Director,Officer; Director,Officer,TenPercentOwner; Officer; Officer,TenPercentOwner | CEO and President; President | 11 | 2015–2020 | person page Fuzzy |
| Ritter Ira E. | Director; Director,Officer; Director,Officer,TenPercentOwner | COB, CSO; Exec. Chairman, CSO | 12 | 2015–2022 | |
| Step Michael D | Director,Officer | CEO | 8 | 2015–2018 | person page Fuzzy |
| Stonehenge Partners LLC | TenPercentOwner | 2 | 2015 | ||
| Mochizuki Ellen F. | Officer | VP, Finance | 3 | 2015–2017 | |
| Merino William M. | Director | 6 | 2017–2020 | ||
| Benjamin Jeffrey S | Officer | VP of Finance | 2 | 2017–2018 | |
| Beck John W | Officer | Chief Financial Officer | 4 | 2018–2020 | |
| Abdul-Ahad Wajdi | Officer | Vice President, R & D, CSO; VP, R&D, CSO | 4 | 2020–2022 | |
| David Richard A. | Director | 4 | 2020–2022 | ||
| Korenberg Matthew E | Director | 3 | 2020–2022 | ||
| Kruger Kurt H | Director | 7 | 2020–2022 | ||
| Lotz Christopher L. | Officer | Vice President of Finance, CFO; VP of Finance, CFO. | 5 | 2020–2022 | |
| Poirier Michael S. | Director,Officer | Chairman and CEO; Chairman, CEO & President; Chairman, President and CEO; Chairman, President & CEO; Chairman, President & CEO. | 6 | 2020–2022 | |
| SEKISUI DIAGNOSTICS, LLC | TenPercentOwner | 2 | 2020 | ||
| Sinha Shishir K. | Officer | Vice President of Operations; VP, COO & Secretary; VP of Operations | 4 | 2020–2022 | |
| BROIDRICK AMY S. | Director; Director,Officer | EVP, Chief Strategy Officer; Executive VP, CSO; President/ChiefStrategyOfficer; President/CSO | 7 | 2020–2022 | |
| EMERY SIDNEY W JR | Director | 3 | 2020–2022 | ||
| ARSHAD TARIQ | Officer | SVP/Chief Medical Officer | 4 | 2021–2022 | |
| PRICE CODY | Director | 1 | 2024 | ||
| BECHER CAMPBELL | Director | 1 | 2024 | ||
| LIM ROBERT BRADLEY | Director | 1 | 2024 | ||
| Braeden Lichti | Director | 1 | 2024 | ||
| Bensler Graydon | Director | 1 | 2024 | ||
| FARADAY FUTURE INTELLIGENT ELECTRIC INC. | TenPercentOwner | 1 | 2025 | ||
| Wang Jiawei | Officer | Co-Chief Executive Officer | 1 | 2025 | |
| Shi Chen | Director | 1 | 2026 | ||
| Dodier Jason Evan | Director | 1 | 2026 |
Everyone who filed an insider report for this company, from the SEC’s Insider Transactions Data Sets (2006 on). Person pages are matched by name and state only.
Private offerings before or after (Form D)
| First filed | Issuer | Industry | Offering | Sold | Investors | Filings |
|---|---|---|---|---|---|---|
| 2025-08-13 | Qualigen Therapeutics, Inc. | Biotechnology | $4,500,000 | $4,500,000 | 14 | 1 |
| 2024-11-22 | Qualigen Therapeutics, Inc. | Biotechnology | $5,100,000 | $5,100,000 | 33 | 1 |
| 2018-11-09 | RITTER PHARMACEUTICALS INC | Biotechnology | $6,000,000 | $6,000,000 | 11 | 1 |
| 2014-12-16 | RITTER PHARMACEUTICALS INC | Pharmaceuticals | $5,670,054 | $3,693,875 | 4 | 1 |
| 2012-02-23 | RITTER PHARMACEUTICALS INC | Other Health Care | $3,500,000 | $526,445 | 1 | 1 |
Data: SEC EDGAR. The quarterly full index (every S-1, S-1/A, F-1 and F-1/A since 1993, with the pricing prospectus, notice of effectiveness and withdrawal request of each registrant) and the company submissions data (SIC, state of incorporation, address, EIN, tickers, former names). Company details are what EDGAR holds today, not at the time of the filing.
Also on this site Fuzzy
| Record | Name as filed | Where | Dataset | Matched by |
|---|---|---|---|---|
| Form D issuer | Qualigen Therapeutics, Inc. | CA | Form D private offerings | CIK (EXACT) |
| SEC filer | AIxCrypto Holdings, Inc. | SEC filers (EDGAR) | CIK (EXACT) | |
| Trademark owner | FF EAI Robotics Ecosystem Inc. | CA | Trademarks (USPTO) | name and state |
| Form 5500 plan sponsor | QUALIGEN THERAPEUTICS, INC | EIN (EXACT) | ||
| Person page | Andrew J Ritter | People (Form 990 officers, directors and employees) | officer, director or 10% owner on the company's Forms 3, 4 and 5 (Director,Officer) | |
| Person page | Michael D Step | People (Form 990 officers, directors and employees) | officer, director or 10% owner on the company's Forms 3, 4 and 5 (Director,Officer) |
Matched by an identifier (EIN, CIK, CRD), by name and state or city, or by street address; a shared name or address is not proof of the same person or organization. Every link says how it was made; how the cross-referencing works.
Others with the same interests
SIC industry Finance Services, CA first:
- Marygold Companies, Inc. CA
- Lite Strategy, Inc. CA
- NATE'S FOOD CO. CA
- BLACKHAWK NETWORK HOLDINGS, INC CA
- Yueda Digital Holding CA
- SEQUOIA-LEGATO, INC CA
- PROSPER MARKETPLACE, INC CA
- FINCERA INC. CA
- WEALTHFRONT CORP CA
- Oportun Financial Corp CA
In other datasets, the same topic (Finance) in CA:
- Lobbying client: A16Z CAPITAL MANAGEMENT FKA ANDREESSEN HOROWITZ (Federal lobbying (LDA))
Interests: Finance Services · Finance